Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OCT-598 as a Single Agent and in Combination With Standard-of-Care Treatment in Patients With Advanced Solid Tumors

NCT07358806 is registered in ClinicalTrials.gov with Oscotec Inc. as lead sponsor.

NCT NCT07358806
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07358806 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of OCT-598 as a Single Agent and in Combination With Standard-of-Care Treatment in Patients With Advanced Solid Tumors
Lead sponsor
Oscotec Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
December 18, 2025
Completion date
December 31, 2027
Enrollment
51 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastric/gastroesophageal junction cancer, head and neck cancer, non-small cell lung cancer, prostate cancer, solid tumor